VAW00001: Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
Study Details
Study Description
Brief Summary
The primary objectives of the study are:
-
To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose.
-
To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
The secondary objectives of the study are:
-
To describe binding antibody profile from Day 1 to Day 387 of each study intervention group.
-
To describe the neutralizing antibody profile from Day 90 to Day 387 of each study intervention group.
-
To describe the occurrence of virologically-confirmed COVID-19-like illness and serologically-confirmed SARS-CoV-2 infection.
-
To evaluate the correlation/association between antibody responses to SARS-CoV-2 mRNA vaccine and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
The duration of each participant's participation in the study will be approximately 365 days post-last injection: approximately 386 days duration for participants receiving 2 injections and approximately 365 days duration total for participants receiving a single injection.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Group 1 1 injection of SARS-CoV-2 mRNA vaccine formulation 1 at Day 1 |
Biological: SARS-CoV-2 mRNA vaccine formulation 1
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
|
Experimental: Group 2 1 injection of SARS-CoV-2 mRNA vaccine formulation 2 at Day 1 |
Biological: SARS-CoV-2 mRNA vaccine formulation 2
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
|
Experimental: Group 3 1 injection of SARS-CoV-2 mRNA vaccine formulation 3 at Day 1 |
Biological: SARS-CoV-2 mRNA vaccine formulation 3
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
|
Placebo Comparator: Group 4 1 injection of placebo at Day 1 |
Biological: Placebo (0.9% normal saline)
Pharmaceutical form: Liquid Route of administration: Intramuscular injection
|
Experimental: Group 5 2 injections of SARS-CoV-2 mRNA vaccine formulation 1 at Day 1 and Day 22 |
Biological: SARS-CoV-2 mRNA vaccine formulation 1
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
|
Experimental: Group 6 2 injections of SARS-CoV-2 mRNA vaccine formulation 2 at Day 1 and Day 22 |
Biological: SARS-CoV-2 mRNA vaccine formulation 2
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
|
Experimental: Group 7 2 injections of SARS-CoV-2 mRNA vaccine formulation 3 at Day 1 and Day 22 |
Biological: SARS-CoV-2 mRNA vaccine formulation 3
Pharmaceutical form: Sterile suspension Route of administration: Intramuscular injection
|
Placebo Comparator: Group 8 2 injections of placebo at Day 1 and Day 22 |
Biological: Placebo (0.9% normal saline)
Pharmaceutical form: Liquid Route of administration: Intramuscular injection
|
Outcome Measures
Primary Outcome Measures
- Presence of immediate adverse events [Within 30 minutes after vaccination]
Immediate adverse events include unsolicited systemic adverse events occurring within 30 minutes after vaccination
- Presence of solicited injection site reactions and systemic reactions [Within 7 days after vaccination]
Injection site reactions: injection site pain, erythema and swelling. Systemic reactions: fever, headache, malaise, myalgia, arthralgia and chills.
- Presence of unsolicited adverse events [Within 21 days after vaccination]
Adverse events other than solicited reactions.
- Presence of medically attended adverse events [From Day 1 to Day 387]
A medically attended adverse event is a new-onset or a worsening of a condition that prompts the participant to seek unplanned medical advice at a physician's office or Emergency Department
- Presence of serious adverse events (SAE) and adverse events of special interest (AESI) [From Day 1 to Day 387]
SAEs are collected throughout the study.
- Presence of out-of-range biological test results [From Day 1 up to 8 days post-last injection]
Number of participants with biological safety assessment values out of normal range (as per the laboratory performing the test) are considered. The assessment include white blood cell count, hemoglobin, platelet count, clinical chemistry parameters, and coagulation parameters.
- Neutralizing antibody titer [From Day 1 to Day 36]
Neutralizing antibody titers expressed as geometric mean titers.
- Fold-rise in neutralizing antibody titer [From Day 1 to Day 36]
Fold-rise in serum neutralization titer post-vaccination relative to Day 1
- 2-fold and 4-fold rise in neutralizing antibody titer [From Day 1 to Day 36]
Fold-rise relative to Day 1.
- Occurrence of neutralizing antibody seroconversion [From Day 1 to Day 36]
Seroconversion is defined as baseline values below lower limit of quantification (LLOQ) with detectable neutralization titer above assay LLOQ post-vaccination
Secondary Outcome Measures
- Binding antibody concentration [From Day 1 to Day 387]
- Binding antibody concentration ratio [From Day 1 to Day 387]
Fold-rise in binding antibody concentration postvaccination relative to Day 1
- Fold-rise in binding antibody concentration (post/pre) ≥ 2 and ≥ 4 [From Day 1 to Day 387]
- Neutralizing antibody titers at Day 91 to Day 387 [From Day 91 to Day 387]
- Fold-rise in neutralizing antibody titer at Day 91 to Day 387 [From Day 91 to Day 387]
Fold-rise in serum neutralization titer post-vaccination relative to Day 1
- 2-fold and 4-fold rise in neutralizing antibody titer at Day 91 to Day 387 [From Day 91 to Day 387]
- Occurrence of neutralizing antibody seroconversion at Day 91 to Day 387 [From Day 91 to Day 387]
Seroconversion is defined as baseline values below LLOQ with detectable neutralization titer above assay LLOQ post-vaccination
- Occurrences of virologically-confirmed COVID-19-like illness [From Day 1 to Day 387]
Virologically-confirmed COVID-19-like illness is defined as a positive result for SARS CoV-2 by Nucleic Acid Amplification Test (NAAT) on a respiratory sample in association with a COVID-19-like illness
- Occurrences of serologically-confirmed SARS-CoV-2 infection [From Day 1 to Day 387]
Serologically-confirmed COVID-19-like illness is defined as a positive result in serum for the presence of antibodies specific to SARS-CoV-2 detected by immunoassay
- Correlates of risk/protection based on antibody responses to SARS-CoV-2 [From Day 1 to Day 387]
Correlate analysis considering virologically-confirmed COVID-19-like illness and/or serologically confirmed SARS CoV 2 infection
Eligibility Criteria
Criteria
Inclusion criteria :
-
Aged ≥ 18 years on the day of inclusion.
-
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
-
Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, or surgically sterile.
OR
- Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first vaccination until at least 12 weeks after the last vaccination.
A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the study intervention.
-
Informed Consent Form has been signed and dated.
-
Participant not eligible to receive, based on local guidance, or if eligible does not intend to receive an authorized/approved COVID-19 vaccine from first vaccination until completion of the key timepoint of Day 43 of follow-up of this study.
Exclusion criteria:
-
History of COVID-19 disease or prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed serologically.
-
Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
-
Chronic illness or condition considered to potentially increase the risk for severe COVID illness or that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion.
-
Known liver disease or fatty liver.
-
Positive test for chronic active Hepatitis B surface antigen, Hepatitis B core antibody, Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody from blood work collected at screening visit.
-
Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on Investigator's judgment.
-
Receipt of immuneglobulins, blood or blood-derived products in the past 3 months.
-
Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome coronavirus [MERS-CoV]).
-
Receipt of any vaccine in the 30 days preceding the first study vaccination or planned receipt of any vaccine in the 30 days following the last study vaccination except for influenza vaccination, which may be received at least 2 weeks before and a minimum of 2 weeks after study vaccines.
-
Receipt of any therapy known to have in-vitro antiviral activity against SARS-CoV-2 within 72 hours prior to the first blood draw or planned use of such therapy 72 hours prior to study immunogenicity blood draws at Day 22 and Day 36.
-
Residence in a nursing home or long-term care facility.
-
Health care workers providing direct patient care for COVID-19 patients.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Investigational Site Number :8400003 | Rolling Hills Estates | California | United States | 90274 |
2 | Investigational Site Number :8400002 | Hollywood | Florida | United States | 33024 |
3 | Investigational Site Number :8400006 | Miami | Florida | United States | 33135 |
4 | Investigational Site Number :8400017 | Iowa City | Iowa | United States | 52242 |
5 | Investigational Site Number :8400007 | Kansas City | Missouri | United States | 64114 |
6 | Investigational Site Number :8400008 | Omaha | Nebraska | United States | 68134 |
7 | Investigational Site Number :8400001 | Rochester | New York | United States | 14609 |
8 | Investigational Site Number :8400010 | Philadelphia | Pennsylvania | United States | 19104 |
9 | Investigational Site Number :8400004 | North Charleston | South Carolina | United States | 29405 |
10 | Investigational Site Number :8400015 | Knoxville | Tennessee | United States | 37920 |
11 | Investigational Site Number :8400009 | Houston | Texas | United States | 77081 |
12 | Investigational Site Number :8400005 | Salt Lake City | Utah | United States | 84107 |
13 | Investigational Site Number :0360003 | Morayfield | Queensland | Australia | 4506 |
14 | Investigational Site Number :0360005 | South Brisbane | Queensland | Australia | 4101 |
15 | Investigational Site Number :0360001 | Melbourne | Victoria | Australia | 3010 |
16 | Investigational Site Number :0360002 | Nedlands | Western Australia | Australia | 6009 |
17 | Investigational Site Number :0760001 | Salvador | Bahia | Brazil | 40415-006 |
18 | Investigational Site Number :0760004 | Campo Grande | Mato Grosso Do Sul | Brazil | 79070-900 |
19 | Investigational Site Number :0760003 | Belo Horizonte | Minas Gerais | Brazil | 30110-063 |
20 | Investigational Site Number :3400002 | Municipio Del Distrito Central | Honduras | 11101 | |
21 | Investigational Site Number :3400001 | San Pedro Sula | Honduras | 21104 |
Sponsors and Collaborators
- Sanofi Pasteur, a Sanofi Company
Investigators
- Study Director: Clinical Sciences & Operations, Sanofi
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VAW00001
- U1111-1251-5486